Back to Wiki

Tesamorelin

Growth Hormone

Overview

A stabilized GHRH analog studied for reducing visceral adipose tissue and improving body composition and lipid metabolism.

Mechanism of Action

Tesamorelin is a synthetic, stabilized analog of growth hormone–releasing hormone (GHRH) that has been studied for its ability to bind the GHRH receptor on pituitary somatotrophs and stimulate endogenous growth hormone release. Downstream, this can increase insulin-like growth factor-1 (IGF-1) signaling and influence pathways involved in lipolysis, adipose tissue distribution, and lipid metabolism.

Reported Research Observations

In preclinical and clinical research contexts, tesamorelin has been associated with reductions in visceral adipose tissue and changes in body composition. Researchers have also observed effects on lipid-related markers and other metabolic parameters, although findings vary by study design and population.

Quick Facts

Commonly Available Vial Sizes
2 mg, 5 mg, 10 mg, 20 mg, 40 mg
Typical Research Dose
2,000 – 3,000 mcg (2 – 3 mg)
Suggested BAC Water
2.1 mL
Category
Growth Hormone

Safety & Handling

Tesamorelin is generally handled as a research-use-only peptide and should be stored according to the supplier’s specifications, typically refrigerated after preparation and protected from repeated temperature fluctuations. In laboratory practice, it is commonly reconstituted with bacteriostatic water when specified by the manufacturer or study protocol, and any handling should follow institutional biosafety and aseptic technique guidelines.

Notes

Available in 2mg, 5mg, 10mg, 20mg vials | Dosing: Once daily, Ongoing, reassess periodically. Route: Subcutaneous (SC)

Commonly Researched Together

Further Reading

For laboratory and research use only. Not for human consumption or clinical use. Information is provided for reference and does not constitute medical advice.